C-ADOIAlector
human genetics, neuroscience, immunology
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ADOI
C-ADOIC-ADOIhuman genetics, neuroscience, immunology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
📊 Stock Price and Market Overview Current stock price: $1.55 (as of June 5, 2025) Market capitalization: Approximately $122 million 52-week range: $0.87 – $6.78 P/E ratio (TTM): Not available (company unprofitable) Earnings per share (EPS, TTM): -$1.26 Beta: 0.76 (indicating lower volatility compared to the market) Industry: Biotechnology CEO: Arnon Rosenthal Website: alector.com 💰 Financial Situation Revenue (2024): $100.56 million (up 3.6% year-over-year) Net loss (2024): $119.05 million (smaller loss compared to previous year) Cash and investments (as of March 31, 2025): $354.6 million, enough to fund operations through mid-2027 (GlobeNewswire) 🧬 Product Development and Clinical Trials Latozinemab (AL001): In Phase 3 (INFRONT-3 trial) for frontotemporal dementia (FTD-GRN). Results expected Q4 2025. AL101/GSK4527226: Phase 2 (PROGRESS-AD trial) for early-stage Alzheimer’s disease. Recruitment completed early April 2025. Alector Brain Carrier Programs: Developing brai
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL003.
This is a multi-centre, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AL002.
A first in human phase 1 study in healthy volunteers and participants with Granulin (GRN) mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics
Terms of Use - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Close Hom … injuries of any kind arising from such content or information. The Terms do not apply to those websites; we suggest contacting those websites directly for information on their policies. Any reference to a linked website or any specific third party product or service by name does not imply an endorsement or recommendation by Alector. Prohibited Conduct. BY USING THE WEBSITE YOU AGREE NOT TO: (a) use the Website for any illegal purpose or in violation of any local, state, natio … OF ALL OTHER PROVISIONS OF THESE TERMS. THE LIMITATIONS IN THIS SECTION 13 WILL APPLY EVEN IF ANY LIMITED REMEDY FAILS OF ITS ESSENTIAL PURPOSE. Dispute Resolution and Arbitration 14.1 Generally. In the interest of resolving disputes between you and Alector in the most expedient and cost-effective manner, and except as described in Section 14.2, you and Alector agree that every dispute arising in connection with these Terms will be resolved by binding arbitration. Arbitration … in court, and can be subject to very limited review by courts. Arbitrators can award the same damages and relief that a court can award. This agreement to arbitrate disputes includes all claims arising out of or relating to any aspect of these Terms, whether based in contract, tort, statute, fraud, misrepresentation, or any other legal theory, and regardless of whether a claim arises during or after the termination of these Terms. YOU UNDERSTAND AND AGREE THAT, BY ENTERING I … sclosed to the arbitrator until after the arbitrator makes a final decision and award, if any. If the dispute is finally resolved through arbitration in your favor, Alector will pay you the highest of the following: (i) the amount awarded by the arbitrator, if any; (ii) the last written settlement amount offered by Alector in settlement of the di
[Form 4] Alector, Inc. Insider Trading Activity | ALEC Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil … in this Form 4 filing. Alector director Richard H. Scheller received an equity grant of 10,833 shares of Common Stock in the form of restricted stock units. These RSUs vest in four equal quarterly installments beginning on June 1, 2026. After this award, he holds 106,199 shares directly. Positive None. Negative None. Insider Trade Summary 1 transaction reported Mixed 1 txn Insider SCHELLER RICHARD H Role null Type Security Shares Price Value Grant/Award Common Stock 10,833 $
Does Alector Sponsor H1B & Green Card Visas? | Ellis Home Services Pricing About Resources Login Schedule a Call Services From employment-based visas to family petitions, adjustment of status, and everything in between—we handle all immigration matters. The options shown here are just some of our most common services. Get In Touch Visa Options H-1B $3,000 H-1B1 $3,000 TN $2,500 O-1 $12,000 L-1 $10,000 J-1 $2,500 E-1/E-2 $10,000 E-3 $3,000 Green Card Options EB-1A $12,000 EB-2 NIW $12,000 EB-2 PERM $12,000 EB-3 PERM $12,000 Other Naturalization $5,000 Resources Tools Visa Sponsors Database … mate your H-1B lottery chances News DHS Proposes 75% Increase to US Citizenship Application Fee Supreme Court Ruling on Birthright Citizenship: What It Means for Families H-1B Visa Update: $100,000 Fee Temporarily Reinstated Following Court Stay Judge Strikes Down Trump's $100,000 H-1B Visa Fee — But Can It Return? Is USCIS Really Ending Adjustment of Status? An Immigration Attorney's Analysis of the May 2026 Memo See all news Articles Birthright Citizenship in the
Our Mission - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Close Home … ? You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites. Continue Cancel Close
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
The Alzheimer's Foundation of America Educating America 10 city tour wrapped up last week in Philadelphia. We have been inspired by the incredible people we have had the privilege of connecting with… | Alector LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a
Alector, LLC H1B Visa Data - Salaries, Applications & Approval Rates | H1BTrends H1BTrends H1B PERM Reports Green Card Calculator NEW H1B Lottery Odds Calculator (FY 2027) Immigration Updates Loading company data... Analyzing thousands of H1B applications Fetching applications Calculating statistics Preparing insights H1BTrends Search 3M+ H1B LCA and PERM labor certification applications from the U.S. Dept. of Labor. Find H1B sponsoring companies, compare salaries by job title and city, check approval rates, and explore employment-based green card data. Data reflects the most recent five f … ross different markets. The data above is sourced from official Labor Condition Application (LCA) records filed with the U.S. Department of Labor. H1B visa sponsorship data is updated quarterly to reflect the most recent filings and approval decisions. Data sourced from U.S. Department of Labor disclosure files. Last updated: 2026-05-17T08:48:04.911Z Frequently Asked Questions about Alector, LLC H1B Sponsorship Does Alector, LLC sponsor H1B visas? What is the average H1B sala
Publications in Immuno-Neurology - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Caree … ? You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites. Continue Cancel Close
BioPharma Corporate Venture Capital Investment Trends (2020 edition) - LucidQuest Ventures Consulting Services Strategic and Tactical Competitive Insights across Therapy Areas Digital Health, Artificial Intelligence & Internet of Everything Gene & Cell Therapy, Rare Diseases Vaccines & Infectious Diseases For Investors Investor Diligence and Decision Support Lucid Diligence Briefs Venture Capital Trends Products LucidWargames (HITL AI-powered workshops) LucidScope (AI Answer Intelligence) QuickAnswers (Rapid Primary Research) LucidSearch (BioPharma-dedicated Search Engine) Case … As; digital and data tech are also of interest Boehringer Ingelheim (BI Venture Fund ): Varied CVC portfolio, with strong focus on cell therapies, new mAbs, drug discovery and other novel tech; oncology and CV remain key interests for BI, which also explores several other TAs Eli Lilly (Lilly Ventures ): CVC focuses on SM, drug development and protein-based drugs with main interests in oncology, inflammation a broad number of other TAs EMD Serono (M Ventures ): Strong focus o … o other tech approaches (including cell & gene therapy) Merck (MRL Ventures Fund): CVC explores general drug development and mAb-based therapeutics, whilst also looking into DNA/RNA-based approaches; onco / haem and CNS are key TAs, alongside infectious and rare diseases Mitsubishi Tanabe (MP Healthcare Venture Management): Low activity by the CVC, with main focus on SM, digital and drug development, across several TAs Novo Nordisk (Novo Ventures): Well-diversified CVC, f … by the CVC which maintains its strong focus on CVMD Novartis (Novartis Venture Fund): CVC has been diversifying outside of the SM space, also looking into cell & gene therapy and protein-based therapeutics; oncology and immunology-related TAs receive increased interest Pfizer (Pfizer Ventures): Diversified CVC, maintaining focus on SM development but also including general drug development and diagnostics in its tech interests; onco, CNS and several other TAs are of key … rests; onco, CNS and several other TAs are of key interest Roche (Roche Venture Fund): Roche’s CVC still focuses on SM development alongside diagnostics, microbiome, mAbs and data tech; CVC continues to be interested in several TAs, with primary focus in oncology and metabolic disease Sanofi (Sanofi Ventures): CVC explores SM and general drug dev
Alector dementia drug, partnered with GSK, fails in key study | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explor … f next year. With about $291 million in cash, the company expects to be able to fund operations through 2027. Add us on Google Share Copy link Email LinkedIn X/Twitter Facebook Print License Filed Under: Clinical Trials BioPharma Dive news delivered to your inbox Get the free daily newsletter read by industry experts Email: Select Newsletter: Daily Dive M-F Select Newsletter: Commercialization Weekly Every Wednesday Select Newsletter: Gene Therapy Weekly Every Thursday Select
Alector, Inc. SEC 10-Q Report — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Alector, Inc. SEC 10-Q Report Alector, Inc. SEC 10-Q Report 2 min read ALEC Alector, Inc., a biotechnology company focused on developing therapies for neurodegenerative diseases, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and key business developments during the period. Financial Highlights Collaboration Revenue : $3.7 million, a decrease of $12.2 million … ipates that its existing cash, cash equivalents, and marketable securities will fund operations into the second half of 2027. The company plans to continue advancing its product candidates and discovery programs, with a focus on developing therapies for neurodegenerative diseases. SEC Filing: Alector, Inc. [ ALEC ] - 10-Q - May. 08, 2025 TradingView US stocks ALEC chart Analyze on Supercharts Latest news More news from TradingView Made by humans English English Select market
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune... Menu Advanced Structure search List search Wish Lists Cart Sign in Sign in For suppliers --> Contact us Catalog of Screening Compounds Screening Libraries Building Blocks Al/ML Data sets new 1B virtual space new Advanced Structure search List search Homepage > Company > Media > Pharma News > 2017 > Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for P … l lead development and commercialization activities. Alector and AbbVie will co-fund development and commercialization and will share global profits equally. Alector will receive a $205 million upfront payment and a potential, future equity investment of up to $20 million . Alector is a portfolio company of AbbVie Ventures. About Alector LLC Alector is a privately-owned biotechnology company whose mission is to harness the immune system to meaningfully treat neurodegenerative … Mission Bay Capital as well as Merck, AbbVie, Amgen and the Dementia Discovery Fund. About AbbVie AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and
AbbVie-Backed Startup Raises $133 Million To Fight Alzheimer's With Immunotherapy Sign Up For Newsletters Games Share a News Tip Featured Featured Breaking News White House Watch Daily Cover Stories Making It Their Way: Six TikTok Creators On Finding A High-Quality Content Strategy That Pays Off | Paid Program The Hidden Tax On Enterprise AI: 1 In 5 Workers Lose A Full Day Every Week | Paid Program Silicon & Steel Editorial Video Series Turning Pressure Into Progress For Your Small Business | Paid Program Uniting To Advance Blood Cancer Research | Paid Program The Enterprise AI Shortc … d include AbbVie Ventures, Amgen Ventures, OrbiMed, Alphabet's venture fund GV, and the Dementia Discovery Fund and at least 12 others. Investors in earlier rounds have also included big names like Merck and Johnson & Johnson's drug arm, Janssen Pharmaceuticals. As part of the funding announcement, Alector also revealed its first three drug candidates. "Conceptually, we are doing what immunoncology is doing for cancer, we are doing for brain disorde … taking those programs through to proof-of-concept studies, then AbbVie will co-fund the development and commercialization of the drugs and split the profits — if they ever make it that far. To stay in the loop with Forbes Health coverage, subscribe to the Innovation Rx newsletter here . Got a tip? Share confidential information with Forbes. Editorial Standards Reprints & Permissions LOADING VIDEO PLAYER... FORBES’ FEATURED Video © 2026 Forbes Media LLC. All Rights Reserv
--> Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation AL001 Successfully Restored Pr --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
Sam Jackson - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membership Opti … clinical development expert, Sam is a board-certified emergency physician with fellowship training in medical toxicology. He has a long history of successful leadership experience in the biopharmaceutical industry. Before joining Neuron23, Sam served as Senior Vice President of Clinical Development at Alector, where he oversaw clinical development and operations while leading programs in Alzheimer’s disease and frontotemporal dementia. Sam led the clinical due-diligence disc
Alector Raises $32M Series C --> VC DATABASE MOBILE APP VENTURE SEARCH ARCHIVE ABOUT US Your Source for Venture Capital and Private Equity Financings Massinvestor/VC News Daily --> Alector Raises $32M Series C Back to Home 2015-09-16 Tweet SAN FRANCISCO, CA, Biotech company has raised $32 million in Series C financing. >> Click here for more funding data on Alector >> To export Alector funding data to PDF and Excel, click here Alector LLC, a biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer's disease and other neurodegenerativ … ent, cure or meaningfully slow its progression. About MRL Ventures MRL Ventures Fund, LLC is the therapeutics-focused seed and early-stage corporate venture fund of Merck & Co., Inc. From our headquarters in Kendall Square, Cambridge and with offices in Mission Bay, San Francisco and Central London, MRL Ventures invests globally in innovative science and transformational therapeutics. We are a team of experienced life-sciences venture capital professionals committed to suppor
Participant List | PepTalk - The Protein Science and Production Week About About the Event Attendee FAQs Get Involved Networking Events Attendee List Media Gallery Testimonials Agenda Conference Programs Symposia Training Seminars BuzZ Sessions Networking Events Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Sponsor/Exhibitor Prospectus Exhibit Contract Current Sponsors 2027 Exhibit Floorplan Exhibit Services Schedule Lead Generation Opportunities Sponsor & Exhibitor Portal Downloads Brochures Podcasts Travel Posters Poster Winners Poster Inform
10-K 1 alec-10k_20191231.htm 10-K alec-10k_20191231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K   (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO  &# … 12 months (or for such shorter period that the registrant was required to submit such files). YES  ☒  NO  ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emergi … 60; • the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; and • our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (JOBS Act). We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we o … ent communications with the FDA, potential priority review, and additionally, a rolling submission of the marketing application. AL001 has successfully demonstrated proof-of-mechanism in the Phase 1b portion of the study in FTD-GRN subjects by restoring PGRN levels in plasma and cerebrospinal fluid (CSF) back to the normal range. In December 2019, we reported additional results from our AL001 Phase 1b study. Eight weeks after the first dose of AL001, a global proteomics profi … xclusivity. This exclusivity precludes the FDA from approving another marketing application for the same indication for that time period, unless the later product is clinically superior. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Overview of FTD FTD is a rapidl
Jan 27-29, 90+ Exhibitors at PMWC 2027 Silicon Valley Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to spea … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Our History Overview - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact C … al of AL002 in early Alzheimer’s disease Received FDA clearance of an IND application for AL101 in the treatment of early Alzheimer’s disease Presented 12-month results from AL001 (latozinemab) Phase 2 clinical study in symptomatic FTD-C9orf72 participants at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders 2022 2021 Presented 12-month results from AL001 Phase 2 clinical study in symptomatic FTD-GR … AL002 Added new investors through $29.5M Series D financing Dementia Discovery Fund, an innovative global investment fund launched in October 2015, chooses Alector for first award 2016 2015 Raised $32M in Series C fund with investment from MRL Ventures, OrbiMed, Polaris, Google Ventures, Topspin Partners, and Mission Bay Capital, among others Named one of 2015’s “Fierce 15” private companies by FierceBiotech Disclosed research focus on immuno-neurology and discovery of 12 le … ollaborative research agreement with Johnson & Johnson Innovation Center to fund one target through proof-of-concept in disease models Alector and Adimab announce strategic alliance to access antibody technologies 2014 2013 Co-founders Arnon Rosenthal, Ph.D., Tillman Gerngross and Errik Anderson launch Alector with announcement of Series A financing from Orbimed and Polaris Ventures Alector moves to life science incubator QB3 Alector is incorporated Selected Alector as th … ? You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites. Continue Cancel Close
About Us - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Close Home Ab … ? You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites. Continue Cancel Close
WCBFM 2026 Attendees | Who Attends the West Coast BFM Show Attendee Info Attendee Registration Conference Schedule WCBFM Exhibitor List Why You Should Attend Exhibitor Info Exhibitor Prospectus Conference Schedule Reasons To Exhibit WCBFM Partial Attendee List WCBFM Floor Plan Exhibitor Application Speaker Form Your Top 50 Invites Sponsorship Promotions Official Show Program Guide Media Kit Testimonials Show Facts Exhibitor Forms Exhibitor Contract PDF Who Exhibits? Program Listing Request A Show Badge Show Program Advertising Exhibitor Services Kit – 2026 Contact Us Attendee Info Attend … edule Reasons To Exhibit WCBFM Partial Attendee List WCBFM Floor Plan Exhibitor Application Speaker Form Your Top 50 Invites Sponsorship Promotions Official Show Program Guide Media Kit Testimonials Show Facts Exhibitor Forms Exhibitor Contract PDF Who Exhibits? Program Listing Request A Show Badge Show Program Advertising Exhibitor Services Kit – 2026 Contact Us West Coast Buildings & Facilities Management Show & Conference Sample Attendee List COMPANY TITLE 10 … opment Attendee Registration Conference Schedule Exhibitor Prospectus Exhibitor Application (510) 888-1661 | [email protected] | proexpos.com Our Shows Nationwide NEBFM Worcester, MA WCBFM Pleasanton, CA COBFM Denver, CO SFBFM Ft. Lauderdale, FL MWBFM Sandy, UT SWBFM Phoenix, AZ MNBFM Minneapolis, MN MABFM Edison, NJ © 2026 Professional Expos Group • ProExpos.com • Contact Us • (510) 888-1661
Pipeline for Neurodegenerative Diseases - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & … ? You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites. Continue Cancel Close
Alector posts 2025 loss, trims R&D, holds $256M cash | ALEC 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … h $256.0 million in cash, cash equivalents, and investments and expects this to fund operations at least through 2027, while advancing programs including AL137, AL050, AL064, and the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) with an interim futility analysis planned in the first half of 2026. Positive None. Negative None. Insights Biotech earnings analyst neutral Revenue fell as past milestones rolled off, while spending dropped and cash runway extends through 2027. Al … equivalents, and investments of $256.0M as of December 31, 2025 are expected to fund operations at least through 2027, giving the company time to progress AL137, AL050, AL064 and the nivisnebart PROGRESS-AD trial. Future updates around the planned interim futility analysis in the first half of 2026 may be important for understanding clinical momentum. 8-K Event Classification 2 items: 2.02, 9.01 2 items Item 2.02 Results of Operations and Financial Condition Financial Disclos … stigational new drug (IND)-enabling studies. The company expects to file an IND application in Q4 2026 / Q1 2027, based on the timing of GMP clinical supply production.   • AL137 is engineered for optimal brain uptake, potency, safety, and convenience. The candidate comprises a high-affinity, fully human antibody that selectively binds PyroGlu3, a validated epitope on toxic amyloid beta found in plaques and retains an active effector function intended to facilitat … through preclinical development. The company is targeting submission of an IND application in 2027.   • AL050 is designed to address key challenges associated with enzyme delivery to the brain, featuring an engineered GCase with improved activity and stability and a silenced effector function to maximize safety, paired with Alector&#
Exhibitors Skip to main content Toggle navigation Login Search Home Icon Legend This session is not in your schedule. This session is in your schedule. Click again to remove it. Exhibitors Home Exhibitors Exhibitors Type here to filter the list All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # Sort by Booth Sort by Company A Favorite 509 Alector, Inc Favorite 410 American Board of Professional Neuropsychology B Favorite 303 BrainWise Media C Favorite 608 CARF International Favorite 502 Cognistat, Inc. D Favorite 610 Dayton Children's Hospital Favorite 305 Drake University/MSCP program
10-K false true 0001653087 3 FY http://alector.com/20211231#CollaborationRevenueMember http://alector.com/20211231#CollaborationRevenueMember December 31 http://alector.com/20211231#CollaborationRevenueMember 0001653087 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001653087 alec:TwoThousandNineteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001653087 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001653087 alec:AdimabMember 2020-12 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth comp … tion; and • the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements. We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, and these forward-looking statements are not guarantee … 4 homozygotes currently in our INVOKE-2 Phase 2 clinical trial. We also plan to submit an additional voluntary amendment to the trial protocol to exclude APOE e4/e4 homozygotes from this trial. The potential impact, if any, of this protocol amendment on timing to complete enrollment of the INVOKE-2 Phase 2 clinical trial is currently being assessed. We are conducting this study under the guidance of an Independent Data Monitoring Committee (IDMC), which is allowed to review u … xclusivity. This exclusivity precludes the FDA from approving another marketing application for the same drug for the same indication for that time period, unless the later product is clinically superior. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Fast Track de
Walk to End Alzheimer's - Lincoln | 💜 Thank you to Organize by Design for being a valued sponsor of the Walk to End Alzheimer’s
%PDF-1.3 %��������� 3 0 obj > stream x���N1 ��y�9s�&� 'R�[@ *�S ���Ђʾ��5�?�\{��x�=�#�p�I��T�Ҏ��1�`_$�����]ys�;���K��+�V��!b5 ~�a���������-�o"���q1�@��&t��y&L���� �N�Ʃl���"� ��=k�� > endobj 4 0 obj > /ExtGState > /XObject > >> endobj 6 0 obj > /Length 51674 >> stream x��K��;r�9_�b��]��H��n����уRJ�� ���~��v�;W �ʐOf��`�$���O��xN�k[>�������ǹl[���!��>��ܧcy��O>��O������d� W����������?��o~N �~�����������3� aNi{@�]�U� ��O�?-Lk �ߘ�St/>� >0�i��i�7`��O�?=�4=M��?������?�yy��v���� ���^���_˵ G��u���v>1�Ƿ�����5� ��jL�+�e���c�N���˟�� �Z��� ��������cYN��}|L�=���5����� … b⋓��O�~��}1���$��)�og(�G�� ��D�WJ�?�~;���ֿ? 0h����鑡cÃ��';� ���S�s#��c����rfp��csg�fOOO K�xs�Ԧ��d�lo}���z�� � �f���>��G �!���=3������zur��K���QwB�_��K��RæO�6�� ��H������(KH(K(�49kr����9�s�ݓ�4�,"c�� ������=�{^����8Ƿ�{U�~���=��k�o�� ����� �����;�u��1�F *���.ؔ�"q����,�[�"�XlFQ#��#0���0� Uƀ1:��J�R�28o��v`�(�,Ē`#�B�G����l�ЏCA%���>"�^�/l�� ]~�&{yQ 5�� �&D�^��L�Ir jS C����W��2 "^M�}Q� �}�E�p;^�n{�� ���^'V�E��=��=���k�HY�m�G�� �V�^�9g� … X�7� [-��Ĥ�S����rpZ&߰��g�� 7��}1;�ї�����\�6����V�9!L8��24ob�~ @ ���7 RFp�� z���&�z(�7@+h�}���gw��|�� Xw�v�P���"��HP��@����Lu�7so.f�K�1�HYQj� UO���Ҁ_��(�I �g}�i�����8��a�H[��!�:�1�:P �֢�7��8��X���7@ � 7 � �g1ƿ���4����R H$k���m�v���1 �hxrj>��A�@�u ��+ � ���6 ��u;m�|��4]P:�b�'�v�} � ���]�4�0e��?ܱ�� O���.�����|���� l-��2�P�-�g^ ���^iZ��O�ߘ\X��fk����ǂ�ٯZ�]mqC(Yܙ��3wW�l�>� �`$k�ْKo (���Ʈ ��P����7�4��F��G�声iu��UB��}1��1�� �S�;B��˞QD
Alector, LLC - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Alector, LLC NEWS JOBS IN THE PRESS NEWS Alzheimer’s disease GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize. April 30, 2026 · 2 min read … e Assets into the Clinic Suliman anticipates filing an Investigational New Drug application with the FDA for the PCD asset this year, and next year filing one for the cystic fibrosis asset. January 24, 2022 · 5 min read · Alex Keown Business GSK and Alector Partner to Develop Immuno-Neurology Treatments The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases … ;· 7 min read Business Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee December 16, 2019 · 5 min read Business Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer December 12, 2019 · 3 min read Biotech Bay Alector Announces Data from On-going Pha … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China March 25, 2020 | 5 min read Twitter LinkedIn Facebook Email Print Innovent Biologics, Inc. and Alector, Inc. jointly announced that they have entered into a licensing agr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Searc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee December 16, 2019 | 5 min read Twitter LinkedIn Facebook Email Print Alector, Inc. (Nasdaq: ALEC), a clinical stage … ultiple R&D organizations, Dr. Scheller is the 2013 recipient of the Lasker Award for discoveries about the mechanism of neurotransmitters. He is currently the Chairman of Research and Development at BridgeBio, and previously held executive leadership positions at 23andMe and Genentech. Dr. Südhof is the Avram Goldstein Professor in the School of Medicine at Stanford University, who won the Nobel Prize in Physiology or Medicine in 2013 for the discovery of a major tr … ler is the 2013 recipient of the Albert Lasker Basic Medical Research Award for discoveries concerning the molecular machinery and regulatory mechanism that underlie the rapid release of neurotransmitters. He is currently the Chairman of Research and Development at BridgeBio. He was previously the head of therapeutics and chief scientific officer at 23andMe from 2015 to 2019. Prior to his role there, Dr. Scheller spent 14 years at Genentech where he was executive vi … f Technology (Caltech). About Thomas Südhof, M.D. Dr. Südhof won the Nobel Prize in Physiology or Medicine in 2013 for discoveries that advanced our understanding of how nerve cells communicate by synaptic transmission. He has been the Avram Goldstein Professor in the School of Medicine at Stanford University since 2008 and is curr
Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne November 16, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the t … ford University School of Medicine, where, among other prizes, he won the Kavli Prize in Neuroscience and the Albert Lasker Award for Basic Medical Research . He is a member of the board of trustees at the California Institute of Technology; a fellow of the American Academy of Arts & Sciences; a member of the National Academy of Sciences; and a member of the National Academy of Medicine. He earned his B.S. in biochemistry from the University of Wisconsin–Madiso … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors August 12, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Alector, Inc. announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors. SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (G … contributions to the field including the American Academy of Neurology Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases, a prestigious honor considered to be the Nobel Prize of Alzheimer’s research. Dr. Yaffe holds a B.S. in biology-psychology from Yale University, an M.D. from the University of Pennsylvania School of Medicine and has completed residencies in neurology and psychiatry at the University of California, San Francisco. “What excites me most … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs July 25, 2018 | 3 min read Twitter LinkedIn Facebook Email Print First three programs to focus on Alzheimer’s disease and frontotemporal dementia First three programs … s discovery platform. Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Perceptive Advisors, Casdin Capital, Polaris Partners, OrbiMed, MRL Ventures, GV, the Dementia Discovery Fund, Mission Bay Capital, Amgen Ventures, and others participated in the financing. “There has been a lack of new approaches to treat the underlying causes of devastating neurodegenerative di … the Stanford University School of Medicine and the recipient of the Nobel Prize in Physiology or Medicine in 2013. According to Dr. Südhof, an incoming member of Alector’s Scientific Advisory Board, “bold, new ideas are imperative to address these significant patient populations that are in great need of treatment options.” “At Alector, our focus is on integrating emerging knowledge in human genetics, immunology, neuroscience, oncology, and large data analytics to treat … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankruptcy Lilly,
Alector, with big ideas about treating dementia, presents a little bit of data Skip to Main Content Eli Lilly Donald Trump Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insu … perils. [email protected] @matthewherper Tags aging biotechnology STAT+ To submit a correction request, please visit our Contact Us page . Trending Eli Lilly dives into hair loss treatments with investment… Eli Lilly dives into hair loss treatments with investment in AI startup Absci FDA drops enforcement against Whoop after it tweaks blood… FDA drops enforcement against Whoop after it tweaks blood pressure feature Eli Lilly gave extraordinary obesity drug
Schmidt – Alector's Art You are using an outdated browser. Please upgrade your browser to improve your experience. 2 2 nd Erlangen International Comic Salon 4 – 7 June 2026 Login My Salon DE EN Home Fair Exhibitors A–Z Comic Exchange A-Z Floor Plan | Comic Fair Schmidt – Alector's Art Artists Exhibitions Events Max und Moritz Award Venues Tickets Archive Press Fair Schmidt – Alector's Art Claudya Schmidt – Alector's Art © Alector Bessemerstr. 95, 12103 Berlin [email protected] www.artstation.com/alectors_art Hall D Stand 131 Small Exhibitor Claudya Schmidt is a c
AL002 / Alector, AbbVie AL002 / Alector, AbbVie - LARVOL DELTA Home Next Prev 1 to 25 Of 59 Go to page 1 2 3 January 10, 2026 TREM2 BINDING SITE MATTERS. VHB937, AN IGSF-BINDING ANTIBODY, TRIGGERS A MICROGLIAL ACTIVATION PROFILE DIFFERENT TO THAT OF A STALK-BINDING ANTIBODY. (ADPD 2026) - "Interestingly, in FIH studies the stalk binding Ab AL002 (DOI:10.1186/s13195-024-01599-1) showed elevation of SPP1 in CSF but decreased for VHB937. Activating TREM2 with an IgSF-binding antibody like VHB937 produces substantially different downstream signaling patterns compared to those produced by bind
Alector is proud to sponsor the UPENN Virtual 2025 FTDC Familial Conference: Uncovering the Genetics of FTD/ALS. This event addresses the unique challenges of familial and genetic forms of these… | Alector LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
--> Alector Reports Strong Q1 2024 Results - ALEC | BioPharmaWatch --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & p … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news. … estimated offering expenses. Management expects that this will be sufficient to fund current operations through 2026. 2024 Guidance. Management is reiterating its guidance for the year ending 2024. The company continues to anticipate collaboration revenue to be between $60 million and $70 million, total research and development expenses to be between $210 million and $230 million, and total general and administrative expenses to be between $60 million and $70 million. Alector
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Failure of GSK-partnered Alzheimer’s drug a fresh setback for Alector | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hemato
Alector stock drops after Alzheimer’s drug fails in Phase II trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product &
Alector launches $208m fundraiser for Alzheimer's R&D with AbbVie | pharmaphorum Skip to main content Thursday 25 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Di
Alector Reports First Quarter 2022 Financial Results and --> Accessibility: Skip TopNav Alector Reports First Quarter 2022 Financial Results and Provides Business Update May 05, 2022 16:05 ET | Source: Alector, Inc. Alector, Inc. Data from INFRONT-2 Phase 2 clinical trial showed that FTD-C9orf72 patients treated with AL001 (latozinemab) demonstrated a trend towards an annual delay in disease progression of approximately 54 percent relative to the ALLFTD matched control cohort INFRONT-2 FTD-C9orf72 cohort represents first clinical dataset from an indication in which treatment with latozi … personnel-related expenses and increase in legal expenses from the arbitration award in 2021 that reduced expenses. Net Loss. For the quarter ended March 31, 2022, Alector reported a net loss of $44.6 million, or $0.54 per share, compared to a net loss of $52.2 million, or $0.66 per share, for the same period in 2021. Cash Position. Cash, cash equivalents, and marketable securities were $868.6 million as of March 31, 2022. Management expects that this will be sufficient to f
--> Alector Announces $75M Public Offering of Common Stock - ALEC | B --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
Alector (ALEC) | Trefis Alector (ALEC) | Trefis | Trefis All Data About Our Story Management Team Investors and Advisors Careers Contact Us Try Trefis Sign In × Try Trefis Sign In All Data About Our Story Management Team Investors and Advisors Careers Contact Us Try Trefis Sign In Tearsheet ALEC Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About ALEC Interactive Breakdown Better Bets vs. ALEC Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Comparisons - Financials - Growth & Margins - Valu … n its other programs. Show less. ALEC in ETFs Weight = ALEC's share of each fund VTI 0.00% IWM 0.00% IWN 0.01% VTWO 0.01% SCHA 0.00% VHT 0.00% IWO 0.00% SCHB 0.00% +1 more covered ETF Valuation & Metrics Valuation Consensus Key Metrics Op. Metrics FYE: 12/31 Forward FYE Now Historical (CYE & TTM) 2027 2026 6/25/26 2025 2024 2023 2022 Share Price $1.79 $1.56 $1.89 $7.98 $9.23 Mkt Cap ($ Mil) 198.5 171.0 185.8 673.5 763.9 + Debt ($ Mil
GSK invests in Alector’s antibodies for neurodegenerative diseases --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section How biochemistry fuels World Cup athletes Meet Jasmine Clark, the self-described ‘mad scientist’ running for the US House Australia’s $1.4 billion PFAS lawsuit could be a global model The road to sustainable rare earth … ity of microglia, helpful immune cells in the brain. Send the reporter feedback Submit a Letter to the Editor for publication Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society Advertisement Enjoyed the article? Share GSK invests in Alector’s antibodies for neurodegenerative diseases The antibodies boost progranulin, a protein that could help treat frontotemporal dementia, Alzheimer’s disease, and more cen.acs.org Advertisement More in N
Alector LLC Secures Series A Financing to Find Cure for Alzheimer's and Related Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Alector LLC Secures Series A Financing to Find Cure for Alzheimer’s and Related Diseases October 31, 2013 | 5 min read Twitter LinkedIn Facebook Email Print San Francisco, California – October 31, 2013 – Alector LLC, a biotech company dedicated to the discovery and development of novel therap … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Alector Strategy and Business Model Skip to content Skip content FIND YOUR CONSULTANT JOIN OUR COMMUNITY Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What we do Consultant directory Press Contact For consultants Join our Community How to start your own practice Events Resources Podcast Members’ forum Umbrex Consult … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What we do Consultant directory Press Contact … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory FIND YOUR CONSULTANT JOIN OUR COMMUNITY Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What we do Consultant directory Press Contact … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory Company Profiles > Alector Strategy and Business Model Alector Strategy and Business Model Executive Overview Alector is a South San Francisco-based, late clinical-stage biopharmaceutical company focused on immuno-neurology , its ter
Alector director receives new stock and option awards | ALEC Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stoc … nstallments beginning July 17, 2026, or in full on the earlier of one year from grant or the next annual meeting. Following these awards, he directly holds 98,650 shares of common stock and 9,450 stock options. Positive None. Negative None. Insider Trade Summary 2 transactions reported Mixed 2 txns Insider Altmeyer Mark Role null Type Security Shares Price Value Grant/Award Stock Option (right to buy) 9,450 $0.00 -- Grant/Award Common Stock 28,700 $0.00 -- Holdings After Tran … ion will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Key Figures RSU grant: 28,700 shares Option grant: 9,450 options Shares held after awards: 98,650 shares +4 more 7 metrics RSU grant 28,700 shares Restricted stock units vesting by June 17, 2027 or next annual meeting Option grant 9,450 options Stock options on common stock granted as of June 17, 2026 Shares held after awar … s held after awards 98,650 shares Common stock directly owned following the RSU grant Options held after awards 9,450 options Total stock options following the new grant RSU vesting date June 17, 2027 Latest vesting date, or earlier at next annual meeting Option vesting start July 17, 2026 Monthly option vesting begins on this date Option expiration June 16, 2036 Expiration date for the stock options Key Terms restricted stock units, RSUs, Stock Option (right to buy), annual … ion will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. /s/ Grace Wong-Sarad, by power of attorney 06/17/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectl
Privacy Policy - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Close H … ird-party websites. The privacy policies and procedures described herein do not apply to such third-party sites; we suggest contacting those sites directly for information on their data collection and distribution policies. Any reference to a linked site or any specific third-party product or service by name does not constitute or imply its endorsement by us, and you assume all risk with respect to its use. Personal Information We Collect We may collect, use, store and transf … rowsing history; search history; information on your interaction with our Site, application, or advertisement; device information (e.g., browser type and version, time zone setting, operating system, IP address) To provide and improve our business and clinical services To provide and improve our Site To comply with our legal and regulatory obligations You Your Device(s) Our Service Providers Geolocation data: Approximate device location via IP address … licy as a whole, please Contact Us at (415) 231-5660 [email protected]. Application Under the California Consumer Privacy Act and California Privacy Rights Act, California residents have certain privacy rights with respect to their Personal Information, which we may collect and process. For purposes of this section, Personal Information does not include: Publicly available information from government records, De-identified or aggregated information, or Other informati … we will only review and fulfill a request from your Authorized Agent if (a) you grant the Authorized Agent written permission to make a request on your behalf, (b) you or the Authorized Agent provides us notice of that written permission, and (c) we are able to verify your and the Authorized Agent’s identity in connection with that notice and the
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
EX-10.19 2 alec-20210630ex10_19.htm EX-10.19 EX-10.19 Exhibit 10.19   *** Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.     COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN ALECTOR, INC. AND GLAXO WELLCOME UK LIMITED                             *** Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclos … to any intellectual property right or other intangible property, the ability to grant to the other Party access or a license or sublicense as provided herein without violating the terms of any agreement with any Third Party and (b) with respect to any tangible material or other item, the legal authority or right to physical possession of such tangible material or item, with the right to provide such tangible material or item to the other Party on the terms set forth herein. 1 … rder, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with any Governmental Authority. 1.65 “GSK Intellectual Property” means GSK Know-How, GSK Patents, GSK’s interest in the Joint Patents, and GSK Sole Inventions, collectively. 1.66 “GSK Know-How” means any Know-How [***]. 1.67 “GSK Manufacturing Know-How” means any [***]. 1.68 “GSK Patents” means Patents (excluding J … D Minor Indications. 1.73 “IND” means an Investigational New Drug Application filed with FDA or a similar application filed with an applicable Regulatory Authority outside of the United States such as a clinical trial application or a clinical trial exemption, or any other equivalent or related regulatory submission, license or authorization. 1.74 “ Initiation ” means, with respect to a Clinical Study, the [***] for such trial. 1.75 “Investi … tion, or method of delivery. 1.84 “MAA” means a Biologics License Application as defined in the FFDCA, or any corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application filed with the EMA pursuant to the centralized approval procedure or with the applicabl
Jobs at Alector | GV You are using an outdated browser. Please upgrade your browser to improve your experience and security. About Team Portfolio News Social Close AI Mode Close Linkedin Instagram Facebook Youtube X Request an AI Summary Gemini ChatGpt Claude Grok perplexity ` About Team Portfolio News Social Linkedin Instagram Facebook Youtube X AI Mode Request an AI Summary Powered by Consider Privacy Terms Linkedin Instagram Facebook Youtube X Privacy Policy News Press Jobs © 2026 GV. All rights reserved.
Alector, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 12 May 2026 Alector, Inc. Public Company | 2013 | California, United States | 100-250 | NASDAQ: ALEC | alector.com Public Company | 2013 | California, United States | 100-250 | NASDAQ: ALEC | alector.com Last update 12 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Alector is at the forefront of developing innovative therapeutics for Alzheimer's disease, dementia, an … on as of March 31, 2026. Management anticipates that this will be sufficient to fund Alector’s operations at least through 2027. About Alector Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Alector Therapeutics for Neurodegenerative Disease Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture  … evelopment strategy seeks to gather disease- and drug-specific insights sooner, apply lessons quickly, and increase our probability of success. Discover our pipeline Helping patients is our purpose. What if diseases of aging weren’t an inevitability? What if we could slow or even halt the seemingly inescapable path toward decline associated with certain conditions? We exist to ask these bold questions, and we seek answers by advancing an understanding of diseases as we discov … ? You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites. Continue Cancel Close
S-1 1 d550248ds1.htm S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on January 7, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ALECTOR, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 82-2933343 (State or other jurisdiction of incorporation or organization) … rs, Casdin Capital, Deerfield Management, Euclidean Capital, Federated Kaufmann Fund, Foresite Capital, GV, Lilly Asia Ventures, Mission Bay Capital, New Leaf Venture Partners, OrbiMed, Perceptive Advisors, Polaris Partners, Section 32, and the Dementia Discovery Fund, a specialist venture capital fund entirely focused on advancing breakthrough treatments for dementia. Our Strategy Our goal is to develop therapies that empower the immune system to cure neurodegeneration. … standards, delaying the adoption of these accounting standards until they would apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, as a result, upon completion of this offering we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies that are not emerging growth companies. 6 Table of Contents THE OFFERING Common stock& … om this offering, together with our existing resources, as follows: (1) to fund Phase 1 trials for each of AL001 and AL002, as well as preparation for Phase 2 and 3 clinical trials for AL001; (2) to advance AL003 and AL101 in and through Phase 1 clinical trials; (3) to fund Phase 2 enabling activities for AL002 and AL003; (4) to continue to advance our preclinical development pipeline into Phase 1 clinical trials; (5) to further de … cal trials; (5) to further develop our Discovery Platform; and (6) to fund working capital and other general corporate activities. See the section titled “Use of Proceeds” for more information. Risk factors See the section of this prospectus titled “Risk Factors” beginning on page 11 and other information
Alector Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Alector Teams Alector Save Saved HQ San Francisco 192 Total Employees Year Founded: 2013 View Website Overview Jobs Offices Is This Your Company? Manage Jobs Jobs at Alector Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. No jobs to discover at this time. back to overview Jobs at similar companies View All Cam
Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia G … e innovative new therapies for Alzheimer's disease - Alector and AbbVie will co-fund development and commercialization and will share global profits equally News provided by AbbVie Oct 24, 2017, 07:00 ET Share this article Share to X Share this article Share to X NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, today announced … l lead development and commercialization activities. Alector and AbbVie will co-fund development and commercialization and will share global profits equally. Alector will receive a $205 million upfront payment and a potential, future equity investment of up to $20 million . Alector is a portfolio company of AbbVie Ventures. About Alector LLC Alector is a privately-owned biotechnology company whose mission is to harness the immune system to meaningfully treat neurodegener … Mission Bay Capital as well as Merck, AbbVie, Amgen and the Dementia Discovery Fund. For more information, please visit www.alector.com . About AbbVie AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary t … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS
Remote Jobs at Alector, Inc. - Virtual Vocations Jobs How It Works Companies Career Center Blog Sign in Post a Job Remote Jobs Sign In More Explore Remote Jobs How it Works Companies Career Center Blog Sign in Post a Job FAQ Remote Jobs at Alector, Inc. About the Company Alector, Inc., founded in 2013 and headquartered in South San Francisco, California, operates in the pharmaceutical industry. The company is dedicated to developing therapies for neurodegenerative diseases by leveraging advanced science and technology. Alector focuses on creating potential first- and best-in-class medicines ai
Our Executive Leadership & Board of Directors - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Cul … target for the cancer drug Erivedge. Dr. Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. He holds a Ph.D. in biology from the Hebrew University of Jerusalem. Previous Next Neil Berkley, M.S., M.B.A. Chief Financial Officer and Chief Business Officer View bio Close Neil Berkley, M.S., M.B.A. Chief Financial Officer and Chief Business Officer Neil Berkley serves as Alector’s Chief Financial Officer and Chief Business Officer, having joined Alector in … target for the cancer drug Erivedge. Dr. Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. He holds a Ph.D. in biology from the Hebrew University of Jerusalem. Previous Next Elizabeth Garofalo, M.D. View bio Close Elizabeth Garofalo, M.D. Dr. Garofalo has served as a member of our Board of Directors since September 2021. Since 2016, Dr. Garofalo has served as the Principal for EAG Pharma Consulting LLC. Prior to that, Dr. Garofalo served in numerous leaders … rom the Indiana University School of Medicine where she completed her pediatric residency. She completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School. Previous Next Paula Hammond, Ph.D. MIT View bio Close Paula Hammond, Ph.D. MIT Dr. Hammond has served as a member of our Board of Directors since March 2020. Dr. Hammond is Institute Professor and the Vice Provost for Faculty at the Massachusetts Institute of Technology (“MIT”), w … he National Academy of Inventors. She received the Margaret H. Rousseau Pioneer Award for Lifetime Achievement by a Woman Chemical Engineer and the Benjamin Franklin Medal in Chemistry from the Franklin Institute. She is a member of the Scientific Advisory Board of Moderna Therapeutics and a member of the Board of Alector Therapeutics and the Boa
Culture and Careers - Alector Close Home About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Privacy Policy Do Not Sell My Personal Information Terms of Use COVID-19 Information Follow Us About Us Our Mission Our History Leadership Our Scientific Approach Publications Pipeline Patients Frontotemporal Dementia (FTD) Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Investors Culture & Careers Contact Cl … lls, particularly in presenting complex information. She presented a scientific proposal, communicating her experiments clearly and concisely despite their complexity. Margaret is instrumental in advancing our early development programs, taking on critical experiments, making important decisions, and ensuring rapid data turnaround to keep projects moving forward. Her ability to work efficiently, troubleshoot in real time, and manage competing priorities has been invaluable to … ? You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites. Continue Cancel Close
Alector, Inc. Company Research Report & Analyst Podcast | Get Alector, Inc.'s Rating (Cyborg Score) Before Making A Decision | AskCyborg Home Company Research Alector, Inc. Alector, Inc. Company Analysis & Research Alector is a late-stage clinical biotechnology company developing therapies focused on counteracting the devastating progression of neurodegenerative diseases. The company combines a proprietary blood-brain barrier delivery platform with multiple clinical-stage programs targeting unmet needs in diseases like Alzheimer's, Parkinson's, and frontotemporal dementia. The … dpoint. However, Alector has $256M in cash as of December 31, 2025, expected to fund operations at least through 2027, with key milestones including a futility analysis for PROGRESS-AD in 1H 2026. Key Strategic Insights for Alector, Inc. The INFRONT-3 trial failure indicates significant translational biology risks that negatively impact the company's therapeutic promise. Q4 2025 quarterly revenue fell to $6.2M with a net loss of $37.3M, reflecting transition from partners
Errik Anderson joining Biomatics Capital Partners - The Boston Globe Skip to main content Sections Epaper Sports Red Sox Patriots Celtics Bruins High Schools Colleges Women's Sports TV & Radio Metro Weather Politics Transportation Education Cambridge & Somerville Around Mass. Investigations Obituaries Death Notices Games & Puzzles Align Crossword Mini Crossword KenKen Sudoku Word Flower Business Technology Economy Housing Real Estate Biotech The Fine Print Bold Types Politics Money, Power, Inequality Climate Spotlight Opinion Ideas Columns and Op-eds Editorials Letters Cartoon … o support new firms. Biomatics had previously raised $200 million for its first fund. The money was invested in more than a dozen companies, including South San Francisco-based Denali Therapeutics. Anderson, the founder and managing partner of Ulysses Diversified Holdings, knows biotech companies well. He co-founded biotechs like Compass Therapeutics of Cambridge, Adimab of Lebanon, N.H., and Alector, also of South San Francisco. A one-time rugby player at Dartmouth College,
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
AbbVie taps Alector for deeper dive into Alzheimer's | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore ou
Checking in with Alector CEO A… ‑ BiotechTV - News ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 13 août 2025 20 min Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter BiotechTV - News Lire Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how A
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases | GSK You are about to access GSK historic archived press release material retained as a corporate record. References to products or their uses may be out of date and not reflect current medical, safety or regulatory information. For clinical information, consult the approved national product label information (SmPC). Continue Cancel Skip to content Skip to search Behind the Science magazine Company Company Purpose, strategy and culture GS … opment and Supply (MDS) Genomic sciences Technology Early careers Early careers Application process Apprentice programmes Internships and placements Graduate programme Graduate programme Business operations Engineering Manufacturing & supply Commercial Research & development Digital & tech Manufacturing sciences & technology Post graduate opportunities Frequently asked questions Veterans Our global and regional hubs How we hire How we hire Fraudulent internet